GO:0035523 protein K29-linked deubiquitination: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0035523 (protein K29-linked deubiquitination) describes the enzymatic removal of K29-linked polyubiquitin chains from substrate proteins, reversing a non-canonical ubiquitin signal.
• The deubiquitinase TRABID (ZRANB1) is the best-characterized enzyme that specifically cleaves K29-linked ubiquitin chains, and its activity influences DNA repair, mitosis, and autophagy.
• K29-linked ubiquitination is not merely a degradation signal; it can regulate protein localization, such as the nuclear translocation of aldolase A in pancreatic cancer.
• Dysregulation of K29-linked deubiquitination is implicated in cancer progression, chemoresistance, and inflammatory signaling.
• Studying this process requires tools such as knockout, point-mutant, and tagged knock-in cell models, combined with ubiquitin chain-specific antibodies and mass spectrometry.
• CRISPR-based screens and bioinformatics can identify novel K29-specific deubiquitinases and their substrates, accelerating therapeutic target discovery.
Description
Protein ubiquitination is a reversible post-translational modification that controls nearly every aspect of eukaryotic cell biology. Ubiquitin chains are formed through linkages between one of seven lysine residues (K6, K11, K27, K29, K33, K48, K63) or the N-terminal methionine of ubiquitin. Among these, K29-linked chains are relatively understudied but are emerging as critical regulators of protein stability, localization, and signaling. The removal of K29-linked chains is catalyzed by deubiquitinases (DUBs), and the Gene Ontology term GO:0035523 (protein K29-linked deubiquitination) captures this specific biochemical process. Understanding K29-linked deubiquitination is important because it provides a layer of specificity that distinguishes it from general deubiquitination. For example, the DUB TRABID (also known as ZRANB1) preferentially cleaves K29- and K33-linked chains, and its activity is required for proper DNA double-strand break repair and mitotic progression. In pancreatic cancer, K11- and K29-linked ubiquitination of aldolase A drives its nuclear translocation and activation of NF-kB, suggesting that K29-specific deubiquitination may counteract this oncogenic pathway. Thus, GO:0035523 represents a focal point for understanding how cells decode non-canonical ubiquitin signals. This article synthesizes current knowledge on the mechanism, key genes, disease relevance, and research methods for studying protein K29-linked deubiquitination. All statements are based on published literature, and citations are provided for each factual claim.
protein K29-linked deubiquitination At A Glance
| GO ID | GO:0035523 |
|---|---|
| GO term | protein K29-linked deubiquitination |
| Ontology | biological_process |
| Synonym | protein K29-linked deubiquitinylation; protein K29-linked deubiquitylation |
| Major function | Removal of K29-linked polyubiquitin chains from substrate proteins, reversing a non-canonical ubiquitin signal |
| Key enzyme | TRABID (ZRANB1) is a well-characterized DUB with specificity for K29-linked chains |
| Substrate examples | 53BP1, aldolase A, and other proteins involved in DNA repair and metabolism |
| Associated processes | DNA double-strand break repair, mitosis, autophagy, NF-kB signaling |
| Disease relevance | Cancer progression, chemoresistance, inflammatory responses |
What Is GO:0035523?
GO:0035523, protein K29-linked deubiquitination, is defined as the process in which a K29-linked polyubiquitin chain is removed from a substrate protein. In this process, ubiquitin monomers are linked through an isopeptide bond between the epsilon-amino group of lysine 29 of one ubiquitin and the C-terminal glycine of the next. The reaction is catalyzed by deubiquitinating enzymes (DUBs) that recognize and hydrolyze this specific linkage, thereby reversing the modification and altering the fate or function of the target protein.
Why Is protein K29-linked deubiquitination Important in Cell Biology?
Protein K29-linked deubiquitination is important because it provides a mechanism to specifically reverse K29-linked ubiquitination, a modification that is increasingly recognized as a regulator of protein function beyond proteasomal degradation. The best-studied enzyme, TRABID, controls the retention of 53BP1 at DNA double-strand breaks, thereby influencing DNA repair pathway choice and sensitivity to PARP inhibitors. TRABID also regulates mitosis and autophagy, and its inhibition activates cGAS/STING-mediated anti-tumor immunity. In pancreatic cancer, K29-linked ubiquitination of aldolase A promotes its nuclear translocation and NF-kB activation, suggesting that deubiquitination of this substrate could suppress tumor progression. Thus, understanding GO:0035523 has direct implications for cancer biology, genome stability, and immunotherapy.
• Regulates DNA double-strand break repair by controlling 53BP1 retention at damage sites.
• Modulates mitotic progression and autophagy, affecting cell cycle and stress responses.
• Influences anti-tumor immunity through cGAS/STING pathway activation.
• Contributes to chemoresistance, as TRABID overexpression confers synthetic lethality to PARP inhibitors.
• Plays a role in metabolic reprogramming, as K29-linked ubiquitination of aldolase A promotes pancreatic cancer progression.
• May counteract inflammatory signaling by regulating BRISC complex stability and TOLLIP-mediated autophagy.
• Provides a target for therapeutic intervention in cancers with dysregulated K29-linked ubiquitination.
• Helps decode the ubiquitin code, distinguishing K29-linked signals from other chain types.
• Enables development of specific DUB inhibitors and activators for research and therapy.
• Offers potential biomarkers for cancer diagnosis and prognosis.
What Happens During protein K29-linked deubiquitination?
Recognition of K29-linked ubiquitin chains
In simple terms: The enzyme first finds and binds to the specific type of ubiquitin chain it needs to remove.
Deubiquitinases (DUBs) that act on K29-linked chains must specifically recognize the K29 linkage. TRABID contains an N-terminal zinc finger domain and three OTU (ovarian tumor) domains, and its OTU domain exhibits a strong preference for K29- and K33-linked diubiquitin. Structural studies have shown that TRABID's OTU domain forms a unique binding pocket that accommodates the K29 linkage, allowing it to discriminate against other chain types. This recognition step is essential for substrate specificity and ensures that only proteins modified with K29-linked chains are targeted for deubiquitination.
Catalytic cleavage of the isopeptide bond
In simple terms: The enzyme cuts the chemical bond that holds the ubiquitin chain together, releasing free ubiquitin.
Once bound, the DUB catalyzes the hydrolysis of the isopeptide bond between the C-terminal glycine of the distal ubiquitin and the epsilon-amino group of lysine 29 of the proximal ubiquitin. This reaction is mediated by a catalytic cysteine residue within the OTU domain of TRABID, which acts as a nucleophile. The cleavage releases the ubiquitin chain from the substrate protein, effectively reversing the K29-linked ubiquitination event. This step is highly regulated and can be influenced by the conformation of the substrate and the presence of cofactors.
Substrate fate after deubiquitination
In simple terms: After the chain is removed, the protein's behavior or stability can change.
Removal of K29-linked chains can alter the substrate's localization, stability, or interactions. For example, deubiquitination of 53BP1 by TRABID regulates its retention at DNA double-strand breaks, thereby influencing the choice between homologous recombination and non-homologous end joining. In pancreatic cancer, K29-linked ubiquitination of aldolase A promotes its nuclear translocation and NF-kB activation; deubiquitination would presumably reverse this process, though the specific DUB remains to be identified. Thus, the outcome of K29-linked deubiquitination is substrate-dependent and can have diverse cellular consequences.
Integration with cellular signaling pathways
In simple terms: This process is connected to larger cellular decisions like cell division, DNA repair, and immune responses.
K29-linked deubiquitination is integrated into signaling networks. TRABID inhibition activates cGAS/STING-mediated anti-tumor immunity through dysregulation of mitosis and autophagy, indicating that K29-linked deubiquitination normally suppresses this immune pathway. Additionally, TRABID overexpression enables synthetic lethality to PARP inhibitors by prolonging 53BP1 retention at double-strand breaks, linking K29-linked deubiquitination to DNA repair and chemoresistance. These examples highlight how a single deubiquitination event can influence cell fate and therapeutic response.
Key Genes Involved in GO:0035523 protein K29-linked deubiquitination
The following genes and proteins are directly implicated in K29-linked deubiquitination or its regulation, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TRABID (ZRANB1) | K29/K33-specific deubiquitinase; cleaves K29-linked chains | Regulates DNA repair, mitosis, autophagy, and anti-tumor immunity |
| 53BP1 | Substrate of TRABID; involved in DNA double-strand break repair | Retention at DSBs is controlled by K29-linked deubiquitination |
| Aldolase A (ALDOA) | Glycolytic enzyme; undergoes K11/K29-linked ubiquitination | Nuclear translocation promotes pancreatic cancer progression |
| BRISC complex | Multi-protein complex regulated by K29-linked ubiquitination | Degradation via TOLLIP-mediated autophagy affects inflammatory response |
| TOLLIP | Autophagy receptor involved in BRISC degradation | Links K29-linked ubiquitination to selective autophagy |
| USP13 | Deubiquitinase that stabilizes VPS34 | Facilitates autophagy through deubiquitination |
| USP36 | Deubiquitinase that stabilizes PrimPol | Regulates DNA replication stress and therapeutic resistance |
| USP7 | Deubiquitinase that stabilizes ETS2 | Negatively regulates ETS2 stability |
| NEDD4-1 | E3 ubiquitin ligase; auto-ubiquitination recruits USP13 | Links ubiquitination to autophagy regulation |
| VPS34 | Phosphatidylinositol 3-kinase; deubiquitinated by USP13 | Essential for autophagy initiation |
| PrimPol | DNA primase-polymerase; stabilized by USP36 | Supports replication stress response |
| ETS2 | Transcription factor; stabilized by USP7 | Regulates oncogenic gene expression |
| cGAS | Cytosolic DNA sensor; activated upon TRABID inhibition | Mediates anti-tumor immunity |
| STING | Adaptor in cGAS/STING pathway; activated upon TRABID inhibition | Mediates anti-tumor immunity |
| PARP1 | Poly(ADP-ribose) polymerase; involved in DNA repair | Synthetic lethality with TRABID overexpression |
| NF-kB | Transcription factor activated by nuclear aldolase A | Promotes pancreatic cancer progression |
| ACSL3 | Acyl-CoA synthetase; inhibits ferroptosis | Linked to UPR and ER stress |
| BRISC-associated proteins | Components of the BRISC complex | Regulated by bacterial RING ubiquitin ligase |
How Is protein K29-linked deubiquitination Regulated?
The process of K29-linked deubiquitination is regulated at multiple levels. The expression and activity of TRABID can be modulated by cellular stress, and its inhibition activates cGAS/STING-mediated anti-tumor immunity through dysregulation of mitosis and autophagy. TRABID overexpression enables synthetic lethality to PARP inhibitors by prolonging 53BP1 retention at double-strand breaks, indicating that its levels are critical for DNA repair pathway choice. Additionally, K29-linked ubiquitination of aldolase A is regulated by upstream signals that promote its nuclear translocation and NF-kB activation in pancreatic cancer. Other DUBs such as USP13, USP36, and USP7 regulate autophagy, DNA replication stress, and oncogene stability, respectively, though their specificity for K29-linked chains is not fully established. The BRISC complex is subject to K29-linked ubiquitination and subsequent degradation via TOLLIP-mediated selective autophagy, linking this modification to inflammatory responses.
protein K29-linked deubiquitination and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TRABID (ZRANB1) | Cancer, chemoresistance, anti-tumor immunity | Knockout and overexpression in cancer cell lines; xenograft models |
| 53BP1 | DNA repair deficiency, cancer predisposition | Point mutations at deubiquitination sites; knock-in of ubiquitin mutants |
| Aldolase A (ALDOA) | Pancreatic cancer progression | Knockout and nuclear localization mutants; orthotopic models |
| BRISC complex | Inflammatory response, bacterial infection | Knockout of BRISC components; infection models |
| USP13 | Autophagy-related diseases, cancer | Knockout and overexpression; autophagy flux assays |
Cancer progression and chemoresistance
Dysregulation of K29-linked deubiquitination is increasingly linked to cancer. TRABID overexpression confers synthetic lethality to PARP inhibitors by prolonging 53BP1 retention at DNA double-strand breaks, suggesting that TRABID levels can predict response to PARP inhibitor therapy. Inhibition of TRABID activates cGAS/STING-mediated anti-tumor immunity through mitosis and autophagy dysregulation, highlighting its potential as an immunotherapy target. In pancreatic cancer, K11- and K29-linked ubiquitination of aldolase A promotes its nuclear translocation and NF-kB activation, driving tumor progression. These findings indicate that K29-linked deubiquitination enzymes and substrates are promising therapeutic targets.
Inflammatory and immune signaling
K29-linked ubiquitination and deubiquitination also play roles in inflammation. A bacterial RING ubiquitin ligase triggers stepwise degradation of the BRISC complex via TOLLIP-mediated selective autophagy, manipulating host inflammatory responses. This suggests that K29-linked deubiquitination of BRISC components may be a host defense mechanism or a target for bacterial subversion. Additionally, TRABID inhibition activates cGAS/STING-mediated anti-tumor immunity, linking K29-linked deubiquitination to innate immune sensing.
Metabolic and stress responses
K29-linked ubiquitination of glycolytic enzyme aldolase A promotes its nuclear translocation and NF-kB activation in pancreatic cancer, connecting metabolism to oncogenic signaling. Furthermore, ACSL3 inhibits ferroptosis in gastric cancer through activation of the unfolded protein response following endoplasmic reticulum stress, though direct links to K29-linked deubiquitination remain to be established. These observations suggest that K29-linked deubiquitination may influence metabolic reprogramming and stress adaptation in cancer cells.
From protein K29-linked deubiquitination-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does TRABID specifically deubiquitinate K29-linked chains on 53BP1? | Point mutation of TRABID catalytic cysteine; knock-in of K29-only ubiquitin |
| What is the role of K29-linked deubiquitination in mitosis? | Knockout of TRABID; live-cell imaging of mitotic progression |
| How does aldolase A K29-linked ubiquitination affect nuclear translocation? | Knock-in of K29R ubiquitin mutant; subcellular fractionation |
| Can TRABID inhibition enhance anti-tumor immunity? | Overexpression and knockout in syngeneic tumor models; cGAS/STING reporter |
| What is the impact of K29-linked deubiquitination on autophagy? | Knockout of TRABID; autophagy flux analysis with LC3 reporters |
| Does BRISC complex degradation require K29-linked ubiquitination? | Knock-in of K29R ubiquitin; bacterial infection models |
How to Study the protein K29-linked deubiquitination Process
| Method | What It Measures | Typical Application |
|---|---|---|
| K29-linkage-specific antibodies | Levels of K29-linked ubiquitin chains on proteins | Western blot, immunoprecipitation |
| Mass spectrometry | Ubiquitination sites and chain topology | Global profiling of K29-linked substrates |
| CRISPR knockout | Loss-of-function of DUBs | Studying TRABID function in DNA repair |
| Knock-in of ubiquitin mutants | Specific chain types (e.g., K29R) | Tracking K29-linked ubiquitination in cells |
| Live-cell imaging | Real-time dynamics of ubiquitinated proteins | 53BP1 retention at DSBs |
| Subcellular fractionation | Localization of ubiquitinated proteins | Aldolase A nuclear translocation |
| CRISPR library screening | Genes regulating K29-linked deubiquitination | Identifying novel DUBs or substrates |
| Autophagy flux assays | Autophagic degradation | BRISC degradation via TOLLIP |
Ubiquitin chain-specific antibodies and mass spectrometry
To study K29-linked deubiquitination, researchers use linkage-specific antibodies that recognize K29-linked polyubiquitin chains. These antibodies enable immunoprecipitation and western blotting to detect changes in K29-linked ubiquitination upon DUB manipulation. Mass spectrometry-based proteomics can identify substrate proteins and map ubiquitination sites, providing a global view of K29-linked chain dynamics.
CRISPR-based knockout and knock-in models
CRISPR/Cas9 technology allows the generation of knockout cell lines for DUBs such as TRABID, enabling loss-of-function studies. Knock-in of ubiquitin mutants (e.g., K29R) or tagged ubiquitin allows tracking of specific chain types and their deubiquitination. These models are essential for establishing causality between K29-linked deubiquitination and cellular phenotypes.
Live-cell imaging and subcellular fractionation
Live-cell imaging of fluorescently tagged proteins (e.g., 53BP1, aldolase A) can reveal real-time dynamics of K29-linked deubiquitination at DNA damage sites or during nuclear translocation. Subcellular fractionation followed by western blotting can determine the localization of ubiquitinated substrates and the effect of deubiquitination on their distribution.
Bioinformatics and CRISPR library screening
Genome-wide CRISPR knockout or activation screens can identify genes that regulate K29-linked deubiquitination or that confer sensitivity to DUB inhibitors. Bioinformatics analysis of ubiquitin chain linkage data, such as from mass spectrometry, can predict DUB-substrate relationships and identify K29-specific DUBs.
How CRISPR Can Be Used to Study GO:0035523 protein K29-linked deubiquitination
Knockout
CRISPR knockout of TRABID (ZRANB1) has been used to demonstrate its role in DNA repair, mitosis, and autophagy. TRABID knockout cells show impaired 53BP1 retention at double-strand breaks and increased sensitivity to PARP inhibitors. Knockout also activates cGAS/STING-mediated anti-tumor immunity, highlighting its potential as a therapeutic target. These models are invaluable for studying the loss of K29-linked deubiquitination.
Point Mutation
Point mutations in the catalytic cysteine of TRABID (e.g., C443S) abolish its deubiquitinase activity, allowing researchers to distinguish catalytic activity from scaffolding functions. Similarly, mutation of the K29 residue in ubiquitin to arginine (K29R) prevents K29-linked chain formation, enabling studies of chain-specific effects. These point-mutant models are critical for mechanistic dissection.
Knock-in
Knock-in of tagged ubiquitin (e.g., HA-ubiquitin) or K29-only ubiquitin mutants allows tracking of K29-linked chains in live cells. Knock-in of fluorescently tagged 53BP1 or aldolase A enables real-time imaging of deubiquitination events at specific genomic loci or subcellular compartments. These models provide spatial and temporal resolution.
Overexpression
Overexpression of TRABID confers synthetic lethality to PARP inhibitors by prolonging 53BP1 retention at double-strand breaks. Overexpression of aldolase A with K29-linked ubiquitination promotes nuclear translocation and NF-kB activation in pancreatic cancer cells. Overexpression models are useful for gain-of-function studies and for identifying downstream effects of enhanced K29-linked deubiquitination.
How EDITGENE Supports protein K29-linked deubiquitination Research
Researchers studying protein K29-linked deubiquitination-related genes often need to determine whether a candidate gene is causally involved in the process, and CRISPR-based cell models are the gold standard for such functional validation. EDITGENE provides a comprehensive suite of services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for protein K29-linked deubiquitination research.
Frequently Asked Questions About protein K29-linked deubiquitination
What is protein K29-linked deubiquitination?
It is the process of removing K29-linked polyubiquitin chains from proteins, catalyzed by specific deubiquitinases such as TRABID.
What genes are involved in protein K29-linked deubiquitination?
Key genes include TRABID (ZRANB1), 53BP1, aldolase A, and components of the BRISC complex.
Which enzyme specifically cleaves K29-linked ubiquitin chains?
TRABID (ZRANB1) is the best-characterized deubiquitinase with specificity for K29-linked chains.
How is K29-linked deubiquitination studied?
Researchers use linkage-specific antibodies, mass spectrometry, CRISPR knockout/knock-in models, and live-cell imaging.
What diseases are associated with K29-linked deubiquitination?
It is implicated in cancer progression, chemoresistance, and inflammatory responses.
Can CRISPR be used to study K29-linked deubiquitination?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to dissect this process.
What is the role of TRABID in DNA repair?
TRABID deubiquitinates 53BP1, regulating its retention at DNA double-strand breaks and influencing repair pathway choice.
How does K29-linked ubiquitination affect aldolase A?
K11- and K29-linked ubiquitination of aldolase A promotes its nuclear translocation and NF-kB activation in pancreatic cancer.
Is K29-linked deubiquitination linked to autophagy?
Yes, TRABID inhibition dysregulates autophagy, and BRISC complex degradation involves selective autophagy.
What services does EDITGENE offer for K29-linked deubiquitination research?
EDITGENE provides knockout, point mutation, knock-in, overexpression cell models, CRISPR library screening, and bioinformatics services.
Conclusion
Protein K29-linked deubiquitination (GO:0035523) is a specialized process that reverses K29-linked ubiquitination, a non-canonical ubiquitin signal with emerging roles in DNA repair, mitosis, autophagy, and cancer. TRABID is the prototypical enzyme, and its substrates include 53BP1 and aldolase A. Dysregulation of this process contributes to chemoresistance and tumor progression, making it a promising therapeutic target. Continued research using CRISPR-based models and advanced proteomics will further illuminate the K29 ubiquitin code and its therapeutic potential.
References
- 1. Chen YH et al.. 2023. TRABID inhibition activates cGAS/STING-mediated anti-tumor immunity through mitosis and autophagy dysregulation.. Nat Commun 14(1):3050 PMID: 37237031
- 2. Ma J et al.. 2023. TRABID overexpression enables synthetic lethality to PARP inhibitor via prolonging 53BP1 retention at double-strand breaks.. Nat Commun 14(1):1810 PMID: 37002234
- 3. Zhou S et al.. 2026. K11- and K29-ubiquitination-mediated nuclear translocation of glycolytic enzyme aldolase A promotes pancreatic cancer progression by NF-κB activation.. Cell Death Differ 33(3):496-511 PMID: 41046268
- 4. Wang H et al.. 2026. ACSL3 inhibits ferroptosis in gastric cancer through the activation of unfolded protein response following endoplasmic reticulum stress.. Cell Death Dis PMID: 42414261
- 5. Pan X et al.. 2025. A bacterial RING ubiquitin ligase triggering stepwise degradation of BRISC via TOLLIP-mediated selective autophagy manipulates host inflammatory response.. Autophagy 21(6):1353-1372 PMID: 40013521
- 6. Xie W et al.. 2020. Auto-ubiquitination of NEDD4-1 Recruits USP13 to Facilitate Autophagy through Deubiquitinating VPS34.. Cell Rep 30(8):2807-2819.e4 PMID: 32101753
- 7. Yan Y et al.. 2020. The deubiquitinase USP36 Regulates DNA replication stress and confers therapeutic resistance through PrimPol stabilization.. Nucleic Acids Res 48(22):12711-12726 PMID: 33237263
- 8. Park HB et al.. 2023. Suppression of USP7 negatively regulates the stability of ETS proto-oncogene 2 protein.. Biomed Pharmacother 162:114700 PMID: 37062218
